志道生物是一家国际领先的抗肿瘤细胞因子药物研发企业，具有国内最全面的抗肿瘤细胞因子开发管线和最多的相关专利数量。其核心管线LTC004在中美临床I期阶段，为国内进度最快，给药剂量全球领先的可成药细胞因子管线。其高效的分子设计平台与核心专利蛋白质定向变复性技术突破现有专利壁垒并有效降低研发成本。志道生物于2014年在北京成立，核心团队成员多来自诺和诺德、强生等头部药企，平均15+年产业及研发经验。志道生物目前以完成多轮融资，目前已与多家头部药企合作，实现项目转让/对外授权超10项。
Leto Laboratories is a world leading biotech in anti-tumor cytokine drug development with the broadest anti-tumor cytokine pipelines and the largest number of related patents in China. The leading asset LTC004 is in the Phase I clinical study in China and the United States, the fastest advanced druggable cytokine in China with global-leading dosage administration. The proprietary protein renaturation technology break through existing patent barriers and provide significant cost leadership. Leto Labs was established in Beijing in 2014. Core team all comes from the leading pharmaceutical companies, Novo Nordisk and Johnson & Johnson, etc., with an average of 15+ years of industry and R&D experience. At present, Leto Labs completed multiple rounds of financing, and has partnered with a number of leading pharma with tech-transfer/out-licensing of more than 10 projects.